Concord Drugs Limited to Consider September Results November 12

Concord Drugs Limited will consider unaudited standalone and consolidated results for the quarter ended September 30, 2026, at its board meeting on November 12, following consolidated June 2026 net sales of ₹20.94 crore, up 53.89% year-on-year.

What will Concord Drugs consider at its November 12 board meeting?

Concord Drugs Limited has informed BSE that its board meeting is scheduled for November 12, 2026, to consider and approve financial results for the quarter ended September 30, 2026. The company has indicated that the board will consider both standalone and consolidated unaudited results.

The update is a routine listed-company disclosure, but it gives investors a defined date for the next set of operating and financial data. The September-quarter numbers will follow a June quarter in which the company reported consolidated net sales of ₹20.94 crore, representing year-on-year growth of 53.89%.

The company said its trading window was closed from September 30, 2026, in connection with the results process. It will remain closed until 48 hours after the declaration of results, which places the stated reopening date at November 15, 2026.

No forward guidance, material business change, or specific expectation for the September quarter was disclosed in the board-meeting intimation. The filing concerns the approval of quarterly financial results rather than a capital-raising, acquisition, dividend, or other corporate action.

How did Concord Drugs perform in the June 2026 quarter?

Concord Drugs reported consolidated June 2026 net sales of ₹20.94 crore, compared with a year-earlier level that resulted in 53.89% year-on-year growth. Net profit for the quarter was ₹1.11 crore, compared with ₹0.53 crore in March 2026, according to the provided quarterly data.

Revenue declined sequentially from ₹37.90 crore in March 2026 to ₹20.95 crore in June 2026. The comparison shows that quarterly sales have varied materially, even as the June quarter recorded a strong year-on-year increase.

Operating profit was ₹2 crore in June 2026, against ₹1 crore in March 2026. Operating profit margin improved to 9.3% in June from 3.0% in March. Earnings per share rose to ₹0.85 in June from ₹0.47 in March.

What is the financial background before the September results?

Concord Drugs approved its audited standalone and consolidated financial statements for the year ended March 2026. Consolidated total revenue for FY26 was ₹78.77 crore, according to the company information provided.

The reported quarterly history shows a sharp rise in revenue to ₹38 crore in March 2026 from ₹17 crore in December 2025, followed by revenue of about ₹21 crore in June 2026. Year-on-year revenue growth was 264.8% in March 2026 and 53.9% in June 2026, based on the quarterly figures provided.

The company was established in 1995 and manufactures finished pharmaceutical formulations, including injectables, dry syrup powder, tissue bio-adhesive products, tablets, capsules, ophthalmic preparations and ready-to-fill pellets. Its company profile also describes it as being among India’s top generics suppliers.

Concord Drugs has identified State Bank of India as its banker and stated that it has not availed credit or guarantee facilities. This indicates that the company has not reported bank borrowing or guarantee usage through that banking relationship in the information provided.

What recent governance actions has Concord Drugs completed?

Concord Drugs completed its 31st Annual General Meeting on September 30, 2026, through video conference. All seven resolutions placed before shareholders were approved, with reported support of 99.9999%.

Shareholders adopted the audited standalone and consolidated financial statements for FY26. They also approved the reappointment of S. Nagi Reddy as a director retiring by rotation, reappointed statutory auditors for a second five-year term, approved related-party transactions for FY27, and ratified cost-auditor remuneration for FY27.

The AGM also approved the reappointment of S. Nagavenkata Hareesh Kumar Solleti and Sumeela Kasu as independent directors. These resolutions addressed board and audit governance matters rather than changes to the company’s operating strategy.

The company has disclosed a pending income-tax demand of ₹258.83 lakh relating to assessment year 2011-12. It also stated earlier that there were no material tax disputes or loan defaults, apart from this disclosed pending demand.

How could the September results matter for investors and operations?

The September results will provide the next reported measure of whether Concord Drugs can sustain year-on-year revenue growth after the June quarter. Investors can compare the outcome with June revenue of ₹20.94 crore, operating margin of 9.3%, and net profit of ₹1.11 crore.

Sequential comparisons may also be important because revenue fell from ₹37.90 crore in March to ₹20.94 crore in June. The company’s reported figures show that revenue and margins have moved unevenly across recent quarters, making the September disclosure relevant to an assessment of current operating performance.

The trading-window closure is a standard insider-trading control during the results period. Market activity may respond after the financial statements are released, but the company has not provided earnings guidance or indicated any expected result outcome.

Conclusion

Concord Drugs will place its September 2026 standalone and consolidated financial results before the board on November 12. The announcement follows a June quarter in which consolidated net sales rose 53.89% year-on-year to ₹20.94 crore, while net profit was ₹1.11 crore and operating margin was 9.3%.

The next item to watch is the board’s approved September-quarter disclosure and the comparison of revenue, profitability and margins with the March and June 2026 quarters. The trading window is scheduled to remain closed until November 15, 2026, following the results announcement.